HC Wainwright Reiterates Buy Rating on AGMB
HC Wainwright reaffirmed its buy rating on AGMB with a $35 price target, a 218.76% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on AGMB with a price target of $35 on June 22, 2026.
- HC Wainwright's $35 price target implies 218.76% upside from AgomAb Therapeutics NV's ($AGMB) current $10.98 share price.
- Shares of AGMB traded at $10.98 on Monday, reflecting investor interest following the analyst rating.
- Other analysts, including Leerink Partners and JP Morgan, also initiated buy ratings earlier this year.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright reaffirmed its positive outlook on AGMB by reiterating a buy rating and setting a price target of $35. This update came on June 22, 2026, with analyst Patrick R. Trucchio providing the insights. The reiteration suggests confidence in AGMB's potential upside.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. reiterated its buy rating on AGMB, maintaining a price target of $35. Earlier this year, on March 3, 2026, Leerink Partners and JP Morgan both initiated buy ratings with targets of $36 and $32, respectively. Morgan Stanley also joined in with a buy rating and a $28 target. These consistent buy ratings indicate a strong consensus among analysts about AGMB's potential.
Other Institutional Activity in AGMB
In recent institutional activity, TCG Crossover Management, LLC opened a new position in AGMB, acquiring 2,053,233 shares valued at approximately $21.5 million. This move highlights growing institutional interest in the company.
AgomAb Therapeutics NV Stock Down 16.6%
Shares of AGMB traded at $10.98 on Monday. The stock's performance and the reiterated buy ratings suggest optimism in the market. While specific fundamental metrics for AGMB are not provided, the analyst ratings and recent institutional investments reflect a positive sentiment.
$AGMB price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Bottom Line
AGMB is attracting attention from both analysts and institutional investors. HC Wainwright's reiterated buy rating with a $35 target underscores this confidence. While the 13F filings and analyst updates provide historical data, they highlight the continued interest in AGMB's growth potential.
Get AgomAb Therapeutics NV alerts
New 13F filings, insider trades, and analyst moves on $AGMB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.